NO982417L - Vektorer og fremgangsmÕter for genoverf°ring til celler - Google Patents

Vektorer og fremgangsmÕter for genoverf°ring til celler

Info

Publication number
NO982417L
NO982417L NO982417A NO982417A NO982417L NO 982417 L NO982417 L NO 982417L NO 982417 A NO982417 A NO 982417A NO 982417 A NO982417 A NO 982417A NO 982417 L NO982417 L NO 982417L
Authority
NO
Norway
Prior art keywords
coat protein
cells
vector
methods
chimeric
Prior art date
Application number
NO982417A
Other languages
English (en)
Norwegian (no)
Other versions
NO982417D0 (no
Inventor
Thomas J Wickham
Imre Kovesdi
Douglas E Brough
Original Assignee
Genvec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/563,368 external-priority patent/US5965541A/en
Priority claimed from US08/701,124 external-priority patent/US5846782A/en
Priority claimed from US08/700,846 external-priority patent/US5962311A/en
Application filed by Genvec Inc filed Critical Genvec Inc
Publication of NO982417D0 publication Critical patent/NO982417D0/no
Publication of NO982417L publication Critical patent/NO982417L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10345—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/40—Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/40—Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source
    • C12N2810/405—Vectors comprising RGD peptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
NO982417A 1995-11-28 1998-05-27 Vektorer og fremgangsmÕter for genoverf°ring til celler NO982417L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US08/563,368 US5965541A (en) 1995-11-28 1995-11-28 Vectors and methods for gene transfer to cells
US08/701,124 US5846782A (en) 1995-11-28 1996-08-21 Targeting adenovirus with use of constrained peptide motifs
US08/700,846 US5962311A (en) 1994-09-08 1996-08-21 Short-shafted adenoviral fiber and its use
PCT/US1996/019150 WO1997020051A2 (fr) 1995-11-28 1996-11-27 Vecteurs et procedes permettant de transferer des genes dans des cellules

Publications (2)

Publication Number Publication Date
NO982417D0 NO982417D0 (no) 1998-05-27
NO982417L true NO982417L (no) 1998-07-06

Family

ID=27415918

Family Applications (1)

Application Number Title Priority Date Filing Date
NO982417A NO982417L (no) 1995-11-28 1998-05-27 Vektorer og fremgangsmÕter for genoverf°ring til celler

Country Status (17)

Country Link
EP (3) EP1616961A1 (fr)
JP (1) JP3420586B2 (fr)
AT (1) ATE382694T1 (fr)
AU (1) AU724189B2 (fr)
BG (1) BG102554A (fr)
BR (1) BR9612685A (fr)
CA (1) CA2236912C (fr)
CZ (1) CZ162398A3 (fr)
EA (1) EA199800475A1 (fr)
EE (1) EE9800160A (fr)
IL (1) IL124654A0 (fr)
IS (1) IS4754A (fr)
NO (1) NO982417L (fr)
NZ (1) NZ323834A (fr)
PL (1) PL327038A1 (fr)
SK (1) SK72298A3 (fr)
WO (1) WO1997020051A2 (fr)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5846782A (en) 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US6465253B1 (en) 1994-09-08 2002-10-15 Genvec, Inc. Vectors and methods for gene transfer to cells
US5962311A (en) * 1994-09-08 1999-10-05 Genvec, Inc. Short-shafted adenoviral fiber and its use
US5770442A (en) * 1995-02-21 1998-06-23 Cornell Research Foundation, Inc. Chimeric adenoviral fiber protein and methods of using same
FR2761689B1 (fr) * 1997-04-02 1999-06-25 Transgene Sa Fibre adenovirale modifiee et adenovirus cibles
DE69828193T2 (de) 1997-10-31 2005-12-01 The Board Of Regents Of The University Of Oklahoma, Norman Hyaluronan synthase gen und seine verwendung
AU2321999A (en) * 1998-01-16 1999-08-02 Genzyme Corporation Adenoviral vectors with modified capsid proteins
US20030017138A1 (en) * 1998-07-08 2003-01-23 Menzo Havenga Chimeric adenoviruses
IL141500A0 (en) 1998-08-27 2002-03-10 Aventis Pharma Sa Targeted adenovirus vectors for delivery of heterologous genes
EP1020529B1 (fr) * 1998-11-20 2005-06-01 Crucell Holland B.V. Vecteurs d'apport de gènes munis d'un tropisme pour les cellules des muscles lisses et/ou les cellules endothéliales
IL133032A (en) * 1998-11-20 2007-06-03 Introgene Bv Adenoviral gene delivery vectors provided with a tissue tropism for smooth muscle cells and /or endothelial cells
CA2364499C (fr) * 1999-03-04 2008-12-23 Introgene B.V. Transduction de cellules ressemblant a des fibroblastes ou a des macrophages et moyens a cet effet
CA2378324A1 (fr) * 1999-07-06 2001-01-11 Leif Lindholm Adenovirus recombinant
US6955808B2 (en) * 1999-09-24 2005-10-18 Uab Research Foundation Capsid-modified recombinant adenovirus and methods of use
CA2407518A1 (fr) * 2000-04-26 2001-11-01 Crucell Holland B.V. Vecteurs d'adenovirus a fibres sans spicule, et leurs utilisations
EP1285079A2 (fr) * 2000-05-31 2003-02-26 University of Saskatchewan Adenovirus bovin modifie avec modification du tropisme
US6579522B1 (en) * 2000-06-27 2003-06-17 Genvec, Inc. Replication deficient adenoviral TNF vector
GB0017720D0 (en) 2000-07-19 2000-09-06 Got A Gene Ab Modified virus
US6573092B1 (en) 2000-10-10 2003-06-03 Genvec, Inc. Method of preparing a eukaryotic viral vector
US20030086903A1 (en) 2001-11-02 2003-05-08 Genvec, Inc. Therapeutic regimen for treating cancer
US20040166091A1 (en) 2003-02-24 2004-08-26 Genvec, Inc. Materials and methods for treating disorders of the ear
AU2004238979B2 (en) 2003-05-14 2008-12-18 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Broadening adenovirus tropism
EP2168603A1 (fr) 2003-11-14 2010-03-31 GenVec, Inc. Posologie thérapeutique pour le traitement du cancer
JP2007228802A (ja) * 2004-03-31 2007-09-13 Dnavec Research Inc 標的細胞への遺伝子の導入方法
EP1737885A2 (fr) 2004-04-12 2007-01-03 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Méthode pour utiliser les vecteurs adénovirals amener une réponse immunitaire
CA2567741A1 (fr) 2004-05-25 2006-03-30 Chimeracore, Inc. Systeme d'administration de medicaments a base de nanoparticules a autoassemblage
CA2620495A1 (fr) 2005-08-31 2007-03-08 Genvec, Inc. Vaccins contre la malaria a base de vecteurs adenoviraux
CA2629163C (fr) 2005-11-10 2017-03-21 Genvec, Inc. Vaccin contre la fievre aphteuse a base de vecteur adenoviral
DE602007005366D1 (de) 2006-04-07 2010-04-29 Chimeros Inc Zusammensetzungen und verfahren zur behandlung von b-zellen-malignomen
WO2010120874A2 (fr) 2009-04-14 2010-10-21 Chimeros, Inc. Agents thérapeutiques chimériques, compositions, et leurs procédés d'utilisation
WO2011047316A1 (fr) 2009-10-16 2011-04-21 The United States Of America, As Represented By The Secretary Department Of Health And Human Services Séquences d'acides nucléiques codant pour des protéines mosaïques extensibles du vih
CA2779632C (fr) 2009-11-09 2019-08-20 Jason Gall Adenovirus simien et procedes d'utilisation
WO2011057254A2 (fr) 2009-11-09 2011-05-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Vaccins à base de vecteur adénoviral simien
WO2012021730A2 (fr) 2010-08-11 2012-02-16 Genvec, Inc. Vaccin contre le virus syncytial respiratoire (vsr)
WO2012083297A2 (fr) 2010-12-17 2012-06-21 Genvec, Inc. Vecteurs adénoviraux avec régions d'hexon modifiées
EP2654786B1 (fr) 2010-12-20 2019-02-20 GenVec, Inc. Vaccin contre la dengue à base d'un vecteur adénoviral
CA2847888A1 (fr) 2011-09-09 2013-03-14 Biomed Realty, L.P. Procedes et compositions de regulation d'un assemblage de proteines virales
WO2013154744A1 (fr) * 2012-04-13 2013-10-17 Cornell University Mise au point d'un vaccin conjugué hautement efficace de deuxième génération à base de nicotine destiné à traiter la dépendance à la nicotine
EP2855669B1 (fr) 2012-05-29 2018-10-10 GenVec, Inc. Vecteurs adénoviraux de sérotype 28 modifiés
PT2880160T (pt) * 2012-08-03 2018-12-17 Cedars Sinai Medical Center Isolamento de mutantes que aumentam o tráfego de proteínas para administração de fármacos
AU2014236207B2 (en) 2013-03-14 2019-05-23 Salk Institute For Biological Studies Oncolytic adenovirus compositions
TWI710635B (zh) 2014-10-09 2020-11-21 美商珍維克公司 編碼人類無調同源物-1(hath1)之腺病毒載體
ES2933174T3 (es) 2016-02-23 2023-02-02 Salk Inst For Biological Studi Expresión génica exógena en adenovirus terapéutico para mínimo impacto sobre la cinética viral
EP3390428B1 (fr) 2016-02-23 2019-09-25 Salk Institute for Biological Studies Dosage à haut débit pour mesurer la cinétique de réplication d'un adénovirus
US11155832B2 (en) 2016-09-30 2021-10-26 Genvec, Inc. Adenovectors for delivery of therapeutic genetic material into T cells
CN110062630A (zh) 2016-12-12 2019-07-26 萨克生物研究学院 肿瘤靶向合成腺病毒及其用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9223084D0 (en) * 1992-11-04 1992-12-16 Imp Cancer Res Tech Compounds to target cells
US5543328A (en) * 1993-08-13 1996-08-06 Genetic Therapy, Inc. Adenoviruses having modified fiber proteins
US5559099A (en) * 1994-09-08 1996-09-24 Genvec, Inc. Penton base protein and methods of using same
US5770442A (en) * 1995-02-21 1998-06-23 Cornell Research Foundation, Inc. Chimeric adenoviral fiber protein and methods of using same

Also Published As

Publication number Publication date
EA199800475A1 (ru) 1998-12-24
SK72298A3 (en) 1998-12-02
WO1997020051A2 (fr) 1997-06-05
IL124654A0 (en) 1998-12-06
BR9612685A (pt) 1999-07-20
CA2236912C (fr) 2006-04-25
NO982417D0 (no) 1998-05-27
ATE382694T1 (de) 2008-01-15
JP3420586B2 (ja) 2003-06-23
JPH11501219A (ja) 1999-02-02
NZ323834A (en) 2000-01-28
AU724189B2 (en) 2000-09-14
EP0863987A2 (fr) 1998-09-16
AU1086897A (en) 1997-06-19
MX9804203A (es) 1998-10-31
EP0863987B1 (fr) 2008-01-02
EE9800160A (et) 1998-12-15
EP1616961A1 (fr) 2006-01-18
IS4754A (is) 1998-05-25
CZ162398A3 (cs) 1998-10-14
BG102554A (en) 1999-04-30
CA2236912A1 (fr) 1997-06-05
EP1518933A1 (fr) 2005-03-30
WO1997020051A3 (fr) 1997-08-28
PL327038A1 (en) 1998-11-09

Similar Documents

Publication Publication Date Title
NO982417D0 (no) Vektorer og fremgangsmÕter for genoverf°ring til celler
ATE382695T1 (de) Targeting von adenoviren mit hilfe von konformationsbeschränkten peptidmotiven
DE69619110D1 (de) Adenovirale vektoren für die gentherapie
DE69637545D1 (de) Chimärisches , adenovirales faserprotein und verfahren zu dessen verwendung
EP0866721A4 (fr) Vecteurs adenoviraux cibles
SG165153A1 (en) Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use
ATE336587T1 (de) Adenoviren-vektor systeme und zelllinien
DE69535103D1 (de) Rekombinanter adenovirus welcher eine chimäre penton-base aufweist
ATE342350T1 (de) Modifizierte adenoviren welche ein faserersatzprotein enthalten
WO1999055868A3 (fr) Proteines fizz
DK0632129T3 (da) Rekombinante foamy-virusvektorer til medicinsk og diagnostisk anvendelse, og fremgangsmåder til at præparere rekombinante foamy-virusvektorer
CA2252493A1 (fr) Gene de la .beta.-galactoside - .alpha. 2,6-sialyltransferase
WO2002086098A3 (fr) Systeme operateur-represseur lac
WO2000009693A3 (fr) Identification du gene responsable du phenotype de la souris 'scurfy' et de son orthologue humain
DK0843731T3 (da) Adenovirusvektorer til genterapi
MX9706290A (es) Secuencias amplificadoras, vectores que portan estas secuencias y sus utilizaciones en composiciones para la expresion de secuencias nucleotidicas en celulas transfectadas, aplicaciones terapeuticas y vacunales.
EP0723014A3 (fr) ADNc du gène DOCK180 et la protéine DOCK180
EP1241186A3 (fr) Protéine gas-6 (growth arrest-specific gene 6) humaine et acides nucléiques le codant
CA2237059A1 (fr) Vecteurs adenoviraux cibles
TH19876A (th) จีนที่ประมวลรหัสและวิธีสำหรับแสดงลักษณะเอนไซม์ชนิดใหม่
IT1276724B1 (it) Vettore plasmidico di espressione per cellule di mammifero

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application